CONVENTION APPLICATION FOR A PATENT
62116/80

I/We (a) A. H. ROBINS COMPANY, INC.

of (b) 1407 Cummings Drive, Richmond, Virginia 23220
United States of America

hereby apply for the grant of a Patent for an invention entitled

(c) 2-AMINO-3-BENZOYL-PHENYLACETAMIDES AND CYCLIC HOMOLOGUES

which is described in the accompanying complete specification. This application is a convention application and is based on the application or applications for a patent or patents or similar protection made in the following country or countries on the following date or dates:

in (d) United States on (e) 26 September 1979 No. (f) 078,860

My/Our address for service is care of ARTHUR S. CAVE & CO., Patent and Trade Mark Attorneys, 1 Alfred Street, Sydney, New South Wales, Australia 2000.

Dated this (g) 5th day of September 1980

(h) A. H. ROBINS COMPANY, INC.
By Their Patent Attorneys
ARTHUR S. CAVE & CO.

J. G. SIELY, F.I.P.A.A.
The present invention is concerned with certain novel 2-amino-3-benzoylphenylacetamides and heterocyclic derivatives thereof and pharmacological methods of treatment, pharmaceutical compositions and use thereof and methods of producing the same. The compounds are anti-inflammatory, antipyretic, analgetic and blood-platelet-aggregation inhibiting agents which exhibit minimal undesirable side effects of gastric irritation on oral administration to living animal bodies.

Claim 1:

A compound selected from the group having the formula:

\[
\begin{align*}
&X \\
&\text{CH} = C \rightarrow \text{N} \rightarrow R^1 \\
&\text{Am} \\
&\text{C} = O \\
&\text{(Y)}_n \\
&\text{R} \\
&\text{R}^2
\end{align*}
\]
wherein:

R is hydrogen and lower alkyl,

R¹ and R² are selected from hydrogen, lower alkyl, cycloalkyl, phenyl and phenyl substituted by lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, and R³ and R² when taken together with the adjacent nitrogen form a heterocyclic residue,

X is hydrogen, lower alkyl, lower alkoxy, halogen and trifluoromethyl,

Y is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkylthio, lower alkyloxythio or lower alkylidioxythio,

Am is primary amino (−NH₂), methylamino or dimethylamino, and

n is 1-3 inclusive.
Short Title: 62116/80

Int. Cl:

Application Number:
Lodged:

Complete Specification—Lodged:
Accepted:
Lapsed:
Published:

Priority:

Related Art:

TO BE COMPLETED BY APPLICANT

Name of Applicant: A. H. ROBINS COMPANY, INC.

Address of Applicant: 1407 Cummings Drive, Richmond Virginia 23220, United States of America

Actual Inventor: 1) James Robert Shanklin, Jr 2) Dwight Allan Shamblee 3) David Allan Walsh

Address for Service: ARTHUR S. CAVE & CO., Patent and Trade Mark Attorneys, 1 Alfred Street, Sydney, New South Wales, Australia, 2000.

Complete Specification for the invention entitled:

2- AMINO-3- BENZOYL-PHENYLACETAMIDES AND CYCLIC HOMOLOGUES

The following statement is a full description of this invention, including the best method of performing it known to me:-

-1-
2-AMINO-3-BENZOYL-PHENYLACETAMIDES
AND CYCLIC HOMOLOGUES

BACKGROUND OF THE INVENTION

1. FIELD OF INVENTION
The present invention is concerned with certain novel 2-amino-3-benzoylphenylacetamides and heterocyclic derivatives thereof and pharmacological methods of treatment, pharmaceutical compositions and use thereof and methods of producing the same. The compounds are anti-inflammatory, antipyretic, analgetic and blood-platelet-aggregation inhibiting agents which exhibit minimal undesirable side effects of gastric irritation on oral administration to living animal bodies.

2. DESCRIPTION OF THE PRIOR ART

South African Patent 68/4682 discloses benzoylphenylacetamides generically having a variety of substituents in indefinite positions on phenyl. None of the specific compounds disclosed therein are aminophenylacetamides.

Generally, in the past, strong anti-inflammatory drugs have been found to produce serious side effects of gastric bleeding and ulceration when administered orally to animals in the effective range. The compounds of the present invention have been found to have the advantage that extremely low incidence of gastric irritation is observed when administered in the range effective for reducing inflammation as compared to indomethacin and the
less irritating 2-amino-3-benzoylphenylacetic acids disclosed in U. S. Patent 4,045,576.

OBJECTS AND SUMMARY OF THE INVENTION

The compounds of the present invention are 2-amino-3-benzoylphenylacetamides illustrated generally by the following formula:

\[
R \quad \text{Am} \\
\text{CH-C-N} \quad \text{R}^1 \\
\text{C=O} \\
\text{X} \\
\text{(Y)}^n \\
\text{R}^2
\]

wherein R is hydrogen and lower alkyl; R\(^1\) and R\(^2\) are hydrogen, lower alkyl, cycloalkyl, phenyl and phenyl substituted by lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, and R\(^1\) and R\(^2\) taken together with the adjacent nitrogen may form a heterocyclic residue; X is hydrogen, lower alkyl, lower alkoxy, halogen and trifluoromethyl; Y is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkylthio, lower alkyloxythio and lower alkylidioxythio; Am is primary amino (−NH\(_2\)), methylamino or dimethylamino, and n is 1-3 inclusive.

The novel compounds of Formula I possess valuable pharmacological properties and are useful when administered internally in effective amount in alleviating inflammation, alleviating pain in an animal afflicted with pain, inhibiting blood-platelet aggregation and combating temperature elevation in living animal bodies but with minimal side effects as compared to some other strong anti-inflammatory agents. Illustrative of the anti-inflammatory activity with minimal side effects is the compound of Example 3; namely, 2-amino-3-(4-chlorobenzoyl)phenylacetamide which was found to have about the same potency as indomethacin but exhibited about only 1/100th as much irritation to the stomach as indomethacin.

The compounds of Formula I exhibit inhibition of platelet aggregation in the test method described by Born, J. of Phys. 162, 67-68 p. (1962) and Evans et al., J. of Expt. Med. 128, 877-894 (1968). The test drugs are administered to rats and after two hours the rats are bled and platelet rich plasma obtained. Collagen was added to the platelet rich plasma to induce platelet aggregation and comparisons were made between control and treated samples.


Antipyretic activity of the compounds of Formula I is demonstrated in the lowering of the febrile response in hyperthermic animals without affecting the rectal temperature of normothermic animals. Hyperthermic response produced by subcutaneous injection of Brewer's yeast in rats is overcome by oral administration of as little as 4-8 mg/kg of compounds of Formula I and no significant change in rectal temperature of normothermic rats is observed.

It is an object of the present invention to provide novel compounds and compositions. Another object is to provide a novel method for the treatment of a living animal body and especially mammalian bodies for the purposes of alleviating inflammation and pain, inhibiting blood-platelet aggregation and treating fevers all with a minimum of undesirable side effects in the gastric and intestinal area. Additional objects will become apparent to one skilled in the art and still other objects will become apparent hereinafter.

In the definitions of symbols in the formulas hereof and where they appear elsewhere throughout this specification,
the terms have the following significance.

The term "lower alkyl" as used herein includes straight and branched chain radicals of up to eight carbon atoms and is exemplified by such groups as methyl, ethyl, propyl, isopropyl, butyl, sec. butyl, tertiary butyl, amyl, isoamyl, hexyl, heptyl and octyl. The term "lower alkoxy" has the formula \(-\text{O-lower alkyl}\).

The term "halogen" when referred to herein includes fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine.

The term "cycloalkyl" as used herein includes primarily cyclic alkyl radicals containing 3 to 12 carbon atoms inclusive and includes such groups as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.

The term heterocyclic residue refers to radicals such as morpholino, pyrrolidino, piperidino, piperazino, and the like.

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

Method of Preparation

The preparation of the compounds of Formula I may be accomplished by reactions which involve the following sequence:

1) \( t-\text{BuOCl} \)
2) \( \text{Et}_3\text{N} \) (ca -70°C. methylene chloride solution)

\[
\begin{align*}
\text{Formula III} & : \\
\text{Formula IV} & : \\
\text{Formula II} & : \\
\text{Formula I} & :
\end{align*}
\]
wherein \( R, R^1, R^2, X, Y \) and \( n \) are as hereinabove defined, except \( Y \) cannot be lower alkylthio or oxides thereof and \( R^3 \) is lower alkyl or phenyl. Additionally, compounds wherein \( Y \) is \(-S\)-alkyl are prepared from compounds of Formula I wherein \( Y \) is \( F \) (fluorine) by the following reaction sequence:

\[
\begin{align*}
\text{CHR-C-NR}^1R^2 & \xrightarrow{NaS-loweralkyl} \text{CHR-C-NR}^1R^2 \\
& \text{S-loweralkyl}
\end{align*}
\]

and compounds wherein \( Y \) is lower alkylxythio or lower alkylidioxythio may be prepared by reacting compounds wherein \( Y \) is lower alkylthio with 1 or 2 moles of sodium metaperiodate or metachloro perbenzoic acid by the following reaction sequence:

\[
\begin{align*}
\text{CHR-C-NR}^1R^2 & \xrightarrow{NaIO_4} \text{CHR-C-NR}^1R^2 \\
& \text{S-loweralkyl}
\end{align*}
\]

or \( 2\text{NaIO}_4 \)}
Compounds of Formula I wherein Am is dimethylamino may be prepared by reacting the corresponding 2-amino compound with sodium cyanoborohydride, formaldehyde, acetonitrile and acetic acid.

The preparation of intermediate compounds of Formula II are more fully illustrated in Preparations 6 to 15. Generally, these intermediates are prepared by first reacting the appropriate 2-aminobenzophenones with t-butylhypochlorite and the appropriate thioacetamide in the cold (-60°C to -70°C.) followed by addition of triethylamine.

The intermediates of Formula II are reduced with Raney nickel to compounds of Formula I in solvent except when \( Y = -S\)-lower alkyl such as tetrahydrofuran and isolated by removing solvent and crystallizing. Compounds of Formula I are prepared as illustrated in the foregoing equation due to interference of Raney Ni on \( -S\)-lower alkyl in the reduction step.
Preparation 1

4-[2-(Methylthioacetyl)]morpholine.

A mixture of 40.2 g (0.3 mole) of ethyl methylthioacetate and 130 g (1.5 mole) of morpholine was heated at reflux for 70 hr. Fractional distillation at reduced pressure gave 45 g (86%) of product b.p. 104-105°C./0.05 mm Hg. on second distillation.

Analysis: Calculated for C₇H₁₃NO₂S: C, 47.98; H, 7.48; N, 7.99
Found: C, 47.55; H, 7.59; N, 8.18

Preparation 2

2-Methylthio-N-methylacetamide.

A mixture of 134 g (1.0 mol) of ethyl methylthioacetate and 310 g (10.0 mol) of methylamine was heated in a bomb at 150°C. for 72 hr. The excess amine and the ethanol produced were removed by distillation and the remaining thin syrup was distilled to give 112 g (94%) of the titled compound as a colorless liquid, b.p. 76°C.-78°C./0.4 mm Hg.

Analysis: Calculated for C₄H₉NOS: C, 40.31; H, 7.61; N, 11.75
Found: C, 39.78; H, 7.69; N, 11.88

Preparation 3

2-Methylthio-N,N-dimethylacetamide.

A mixture of 134 g (1.0 mol) of ethyl methylthioacetate and 360 g (8.0 mol) of dimethylamine was heated in a bomb at 150°C. for 90 hr. The excess amine and the ethanol produced were removed by distillation and the residue was distilled to give 129 g (97%) of the titled compound as a clear colorless liquid, b.p. 76°C.-77°C./0.5 mm Hg.

Analysis: Calculated for C₅H₁₁NOS: C, 45.08; H, 8.32; N, 10.51
Found: C, 43.88; H, 8.41; N, 10.60

Preparation 4

2-(2-Propylthio)acetamide.

To a mixture of 46.7 g (0.5 mole) of 2-chloroacetamide in 200 ml of absolute ethyl alcohol was added in a slow stream, a solution of 38.1 g (0.5 mole) of 2-propanethiol in 100 ml of absolute ethyl alcohol and 40 g of 50% aqueous sodium hydroxide. The mixture was heated at reflux for 1 hr.,
then filtered. The filtrate was concentrated under reduced pressure; the residue was dissolved in methylene chloride and the solution was dried over magnesium sulfate. The mixture was filtered and the filtrate was again concentrated. On standing, the syrupy residue crystallized. Recrystallization from isopropyl ether gave 59.0 g (89%) of white platelets, melting at 52-54°C.

Analysis: Calculated for C$_5$H$_3$NQ: C, 45.08; H, 8.32; N, 10.51
   Found

Preparation 5

2-(1-Propylthio)acetamide.

Utilizing the procedure of Preparation 4 but substituting an equal molar amount of 1-propanethiol for 2-propanethiol, there was obtained 61.2 g (92%) of the title compound. The white crystals melted at 49.5-51.0°C.

Analysis: Calculated for C$_5$H$_3$NOS: C, 45.08; H, 8.32; N, 10.51
   Found

Preparation 6

2-Amino-3-benzoyl-5-chloro-$\alpha$-(methylthio)phenylacetamide.

To a cold (-70°C.) solution of 12.77 g (0.055 mole) of 2-amino-5-chlorobenzophenone in 300 ml of methylene chloride, under nitrogen atmosphere, was added 6.0 g (0.055 mole) of t-butylhypochlorite in 20 ml of methylene chloride. After an additional 15 min stirring period, a suspension of 5.8 g (0.055 mole) of $\alpha$-(methylthio)acetamide in 150 ml of methylene chloride was added. The mixture was stirred at -65°C. for one hour. Triethylamine (5.6 g (0.055 mole)) was added and the solution was allowed to warm to room temperature. The reaction mixture was extracted with several portions of water and the organic layer dried over magnesium sulfate. The volume of solution was reduced in vacuo to about 200 ml and the product crystallized as a yellow solid, m.p. 173.5-174.5°C. Yield was 6.86 g (37.3%).

Analysis: Calculated for C$_{16}$H$_{15}$N$_2$O$_2$Sc1: C, 57.40; H, 4.52; N, 8.37
   Found

   : C, 57.38; H, 4.50; N, 8.51
Preparation 7

2-Amino-3-benzoyl-α-(methylthio)phenylacetamide.

To a cold (-70°C.) solution of 19.7 g (0.10 mole of 2-amino-benzophenone in 300 ml of methylene chloride, under nitrogen atmosphere, was added a solution of 11.5 g (0.10 mole) of 95% t-butylhypochlorite in 30 ml of methylene chloride followed after 10 min by a solution of 10.5 g (0.1 mole) of methylthioacetamide in 300 ml of tetrahydrofuran. The temperature was maintained at or below -55°C. during these additions. After one additional hour at -70°C. the mixture was allowed to warm to room temperature and the precipitate was collected by filtration. The precipitate was slurried in 200 ml of methylene chloride and 11 g (0.11 mole) of triethylamine was added. The mixture was stirred for 5 min. The solution was washed two times with 100 ml of water and the organic phase dried over magnesium sulfate and concentrated under reduced pressure. The residue was washed with diethyl ether and dried to yield 13.0 g (43%) of a light yellow powder, m.p. 153-155°C.

Analysis: Calculated for C₁₆H₁₈N₂O₂S: C, 63.98; H, 5.37; N, 9.33; Found: C, 63.64; H, 5.39; N, 9.25

Preparation 8

2-Amino-3-(4-chlorobenzoyl)-α-(phenylthio)phenylacetamide.

To a cold (-70°C.) solution of 34.6 g (0.15 mole) of 2-amino-4-chlorobenzophenone in 500 ml of methylene chloride was added 17.3 g (0.15 mole) of 95% t-butylhypochlorite, followed after 10 min by a solution of 25.0 g (0.15 mole) of phenylthioacetamide in 400 ml of tetrahydrofuran which was added over a 20 min period. The temperature was maintained at -64°C. or below during these additions. After two hours, 20 g (0.2 mole) of triethylamine was added and the mixture was allowed to warm to room temperature. The mixture was concentrated and the residue partitioned between water and methylene chloride. Material insoluble in either phase was collected by filtration, washed with 20% aqueous ethanol
solution and dried to yield 36 g (61%) of light yellow powder, m.p. 189-191°C.

Analysis: Calculated for C\textsubscript{21}H\textsubscript{17}N\textsubscript{2}O\textsubscript{2}S\textsubscript{1}: C, 63.55; H, 4.32; N, 7.06

Found: C, 63.73; H, 4.36; N, 7.16

Preparation 9

1-(2-(2-Amino-3-benzoylphenyl)-2-(methylthio)acetyl]morpholine.

To a cold (-65°C.) solution of 9.9 g (0.05 mole) of 2-aminobenzophenone and 8.8 g (0.05 mole) of 4-(\(\alpha\)-methylthio)acetamino]morpholine in 200 ml of methylene chloride was added dropwise a solution of 5.8 g (0.05 mole) of 95% t-butyl-hypochlorite in 20 ml of methylene chloride. After one additional hour at -60°C., 5.1 g (0.05 mole) of triethylamine was added and the mixture was allowed to warm to room temperature. The solution was washed two times with 100 ml of water, dried over magnesium sulfate and concentrated under reduced pressure. The residue was chromatographed on 600 g of silica gel eluting first with diisopropylether and finally with 10% acetone in diisopropylether. The eluate was concentrated, the residue dissolved in 150 ml ethanol and the solution poured into 400 ml water. The undissolved solid was collected and crystallized from diethylether and dried.

Yield was 12.3 g (62%) of yellow crystals, m.p. 119-121°C.

Analysis: Calculated for C\textsubscript{20}H\textsubscript{22}N\textsubscript{2}O\textsubscript{5}: C, 64.84; H, 5.99; N, 7.56

Found: C, 65.01; H, 5.99; N, 7.57

Preparation 10

2-Amino-3-benzoyl-5-chloro-\(\alpha\)-[(4-chlorophenyl)thio]-phenylacetamide.

To a cold (-70°C.) solution of 20 g (0.0863 mole) of 2-amino-5-chlorobenzophenone in 500 ml of methylene chloride under nitrogen atmosphere was added a solution of 9.48 g (0.088 mole) of t-butyl hypochlorite in 50 ml of methylene chloride. After an additional 15 min stirring, a solution of 17.35 g (0.0863 mole) of \(\alpha\)-[(4-chlorophenyl)thio]acetamide
in 500 ml of a 50/50 mixture of tetrahydrofuran and methylene chloride was added. The mixture was stirred at -70°C for 2 hr, 8.72 g (0.0863 mole) of triethylamine was added, and the stirred solution was allowed to warm to room temperature over a period of 2 hr. The reaction mixture was extracted with several portions of water and the organic layer dried over magnesium sulfate. The volume of liquid was reduced to about 500 ml. Methylene chloride, 500 ml, was added to precipitate the product which after filtration and drying weighed 16.62 g (44.7%). The yellow solid melted at 198-200°C.

Analysis: Calculated for C_{21}H_{16}N_{2}O_{2}SCl: C, 58.48; H, 3.74; N, 6.49

Found: C, 58.49; H, 3.77; N, 6.67

Preparation 11

2-Amino-3-benzoyl-5-chloro-ω-(phenylthio)phenylacetamide.

To a cold (-70°C.) solution of 80.72 g (0.349 mole) of 2-amino-5-chlorobenzophenone in 1.5 liter of methylene chloride, under nitrogen atmosphere, was added 39.1 g (0.60 mole) of t-butyl hypochlorite in 100 ml of methylene chloride. After stirring for 10 min, a solution of 59.19 (0.354 mole) of ω-(phenylthio)acetamide in 1.5 liter of tetrahydrofuran was added. The mixture was stirred for 1.25 hr at -65°C., 37.5 g (0.371 mole) of triethylamine was added and the solution was allowed to warm to room temperature. The reaction mixture was extracted with several portions of water and the organic layer was dried over anhydrous sodium sulfate. The volume of solution was reduced in vacuo and a yellow solid precipitated which when recrystallized from acetonitrile was a yellow crystalline solid, m.p. 190°-191°C.(d).

Analysis: Calculated for C_{21}H_{17}N_{2}O_{2}SCl: C, 63.55; H, 4.32; N, 7.06

Found: C, 63.62; H, 4.29; N, 7.08
Preparation 12

2-Amino-3-benzoyl-α-(phenylthio)phenylacetamide.

Following the procedure of Preparation 11 but substituting equal molar amounts of 2-aminobenzophenone for 2-amino-5-chlorobenzophenone the title compound was obtained in 57% yield. Recrystallized from methylene chloride-diethyl ether-hexane, the compound melted at 153-154°C.

Analysis: Calculated for C_{21}H_{16}N_{2}O_{2}S: C, 69.59; H, 5.01; N, 7.73

Found: C, 69.33; H, 5.00; N, 7.76

Preparation 13

2-Amino-3-benzoyl-γ-(methylthio)-N-methylphenylacetamide.

A solution of 29.6 g (0.15 mole) of 2-aminobenzophenone in 350 ml of methylene chloride was cooled to -70°C. and 17.9 g (0.15 mol) of 2-methylthio-N-methylacetamide in 20 ml of methylene chloride was added. To the (-70°C.) mixture was added dropwise a solution of 17.2 g (0.15 mole) of 95% t-butylhypochlorite in 30 ml of methylene chloride. The temperature was maintained at or below -65°C. for 1.5 hr, then 15.1 g (0.15 mole) of triethylamine was added rapidly. The solution was allowed to warm to room temperature and was washed with water. The organic solution was concentrated and the residue crystallized when mixed with isopropyl ether. The solid was recrystallized from isopropyl alcohol to give 31 g (65%) of yellow needles, m.p. 149.0-150.0°C.

Analysis: Calculated for C_{17}H_{18}N_{2}O_{2}S: C, 64.94; H, 5.77; N, 8.91

Found: C, 65.24; H, 5.83; N, 8.99

Preparation 14

2-Amino-3-benzoyl-γ-(methylthio)-N,N-dimethylphenylacetamide.

A solution of 29.6 g (0.15 mole) of 2-aminobenzophenone in 350 ml of methylene chloride was cooled to -70°C. and 20.0 g (0.15 mole) of 2-methylthio-N,N-dimethylacetamide was added. To the mixture (-70°C.) was added dropwise a solution of 17.2 g (0.15 mole) of 95% t-butylhypochlorite in 30 ml of
methylene chloride. The temperature was maintained at or below -65°C for 1.5 h, then 15.1 g (0.15 mole) of triethylamine was added rapidly. The solution was allowed to warm to room temperature and was washed with water. The organic solution was concentrated and the residue crystallized when mixed with isopropyl ether. The solid was recrystallized from isopropyl alcohol to give 39.8 g (81%) bright yellow crystals, m.p. 153-155°C.

Analysis: Calculated for C₁₆H₂₀N₂O₂S: C, 65.83; H, 6.14; N, 8.53
Found: C, 65.87; H, 6.15; N, 8.52

Preparation 15
2-Amino-3-(4-fluorobenzoyl)-ν-(n-propylthio)phenylacetamide.

A solution of 21.5 g (0.1 mole) of 4'-fluoro-2-amino-benzophenone in 400 ml of methylene chloride was cooled to -70°C, and 11.5 g (0.1 mole) of 95% t-butylhypochlorite was added over a period of 15 min, keeping the temperature below -65°C. To this solution was added a solution of 13.3 g of 2-n-propylthioacetamide in 50 ml of methylene chloride over a 10 min period. The solution was stirred for 1 hr at -65°C to -70°C, and then allowed to warm to 0°C at which point 10.2 g (0.1 mole) of triethylamine was added. The solution was stirred for 10 minutes and then washed with water. The organic solution was dried over magnesium sulfate. After concentrating under reduced pressure, the residue was crystallized from isopropyl alcohol and dried to give 19.5 g (56%) of yellow crystals melting at 140-142°C.

Analysis: Calculated for C₁₈H₁₉N₂O₂SF: C, 62.41; H, 5.53; N, 8.09
Found: C, 62.34; H, 5.58; N, 8.04
Preparation 16

In the same manner as given in Preparation 8, 2-amino-3-(2-fluorobenzoyl)-α-(phenylthio)phenylacetamide, 2-amino-3-(4-trifluoromethylbenzoyl)-α-(phenylthio)phenylacetamide, 2-amino-3-(2,4-dichlorobenzoyl)-α-(phenylthio)phenylacetamide, and 2-amino-3-(2,4-difluorobenzoyl)-α-(phenylthio)phenylacetamide, are prepared from phenylthioacetamide, t-butylhypochlorite, and 2-amino-2'-fluorobenzophenone, 2-amino-4'-trifluoromethylbenzophenone, 2-amino-2',4'-dichlorobenzophenone, and 2-amino-2',4'-difluorobenzophenone.

Preparation 17

2-Amino-3-benzoyl-5-chloro-α-(methylthio)-N-methylphenylacetamide.

To a solution of 38.3 g (0.166 mole) of 2-amino-5-chlorobenzophenone in 1 liter of methylene chloride cooled to -70°C. under an atmosphere of nitrogen was added 18.05 g (0.167 mole) of t-butylhypochlorite. The solution was stirred for 15 min and then a solution of 20.3 g (0.171 mole) of 2-methylthio-N-methylacetamide in 100 ml of methylene chloride was added. The solution was stirred at -70°C. for 2 hrs and 25 ml of triethylamine was added. While stirring, the solution was allowed to warm to room temperature followed by extraction with water and drying of the organic layer with magnesium sulfate. The volume of the solution was reduced to about 400 ml, ether was added and the solution placed in a refrigerator at about 0°C. overnight. The solid which crystallized was dried under high vacuum for about 4 hr at 50°C. Weight of the product was 31.56 g (54.6%) which melted at 170-171°C.

Analysis: Calculated for C₁₇H₁₇N₂O₂SCl: C, 58.53; H, 4.91; N, 8.03

Found: C, 58.68; H, 4.91; N, 8.13
Preparation 18
3-Benzoyl-2-(N-methylamino)-α-(methylthio)phenylacetamide.

When in accordance with the procedure of Preparation 7, 2-N-methylaminobenzophenone is substituted in equimolar amount for 2-aminobenzophenone, the title compound is obtained.
Example 1

2-Amino-3-benzoyl-5-chlorophenylacetamide.

A mixture of 21.34 g (0.0639 mole) of 2-amino-3-benzoyl-5-chloro-α-(methylthio)-phenylacetamide and excess Raney nickel in a mixture of 900 ml of absolute ethanol and 200 ml of dimethylformamide was stirred at room temperature for 45 min. The mixture was filtered through celite to remove the Raney nickel. The solvent was removed in vacuo to give a yellow solid which when recrystallized melted at 213.5-215.0°C.(d).

Analysis: Calculated for C_{15}H_{14}N_{2}O_{3}Cl: C, 62.40; H, 4.54; N, 9.70

Found: C, 62.35; H, 4.58; N, 9.74

Example 2

2-Amino-3-benzoyl-phenylacetamide.

To an agitated solution of 9.7 g (0.032 mole) of 2-amino-3-benzoyl-α-(methylthio)-phenylacetamide in 100 ml of tetrahydrofuran was added 80 g of wet Raney nickel (washed 3 times with water and 3 times with tetrahydrofuran). After 10 minutes the mixture was filtered to remove Raney nickel and the filtrate concentrated under vacuum. The residue was crystallized from isopropyl alcohol to give 6.0 g (73%) of yellow needles, m.p. 178.5-180.0°C.

Analysis: Calculated for C_{15}H_{14}N_{2}O_{2}: C, 70.85; H, 5.55; N, 11.02

Found: C, 70.53; H, 5.53; N, 11.04

Example 3

2-Amino-3-(4-chlorobenzoyl)phenylacetamide.

To an agitated solution of 28.5 g (0.077 mole) of 2-amino-3-(4-chlorobenzoyl)-α-(phenylthio)phenylacetamide in 1 liter of tetrahydrofuran was added 230 g of wet Raney nickel (washed 3 times with water and 3 times with tetrahydrofuran). After 15 minutes the mixture was filtered and the filtrate concentrated under reduced pressure to give 17.4 g (84%) of yellow crystalline solid. Recrystallization from isopropyl alcohol followed by recrystallizing twice from absolute ethanol gave yellow needles, m.p. 212-215°C.
Example 4

4-(2-(2-Amino-3-benzoylphenyl)acetyl)morpholine.

To an agitated solution of 18.5 g (0.05 mole) of 4-[2-(2-amino-3-benzoylphenyl)-2-(methylthio)acetyl]morpholine in 300 ml of tetrahydrofuran was added 150 g of wet Raney nickel. After 15 minutes the mixture was filtered and the filtrate concentrated under reduced pressure. After recrystallization of the residue from isopropyl alcohol, there was obtained 13.3 g (82%) of bright yellow crystals, m.p. 156.5-158.5°C.

Analysis: Calculated for C₁₅H₁₉N₂O₃: C, 70.35; H, 6.22; N, 10.44

Found : C, 70.24; H, 6.21; N, 10.52

Example 5

2-Amino-3-benzoyl-N-methylphenylacetamide.

A solution of 22.5 g (0.072 mol) of 2-amino-3-benzoyl-α-(methylthio)-N-methylphenylacetamide in 400 ml of tetrahydrofuran was treated with 160 g of wet Raney nickel (washed 3 times with water and 3 times with tetrahydrofuran) for 10 minutes. The mixture was filtered and the filtrate was concentrated. The residue was crystallized from isopropyl alcohol to give 17.2 g (89%) of yellow needles, m.p. 145-146°C.

Analysis: Calculated for C₁₆H₁₈N₂O₂: C, 71.62; H, 6.01; N, 10.44

Found : C, 71.76; H, 6.05; N, 10.52

Example 6

2-Amino-3-benzoyl-N,N-dimethylphenylacetamide.

A solution of 33.0 g (0.1 mol) of 2-amino-3-benzoyl-α-(methylthio)-N,N-dimethylphenylacetamide in 500 ml of tetrahydrofuran was treated with 240 g of wet Raney nickel (washed 3 times with water and 3 times with tetrahydrofuran) for 10 minutes. The mixture was filtered and the filtrate ...
was concentrated. The residue was crystallized from isopropyl alcohol to give 27.2 g (96%) of yellow needles, m.p. 123-124°C.

**Analysis:** Calculated for C₁₇H₁₈N₂O₂: C, 72.32; H, 6.43; N, 9.92

Found: C, 72.34; H, 6.42; N, 9.98

**Example 7**

2-Amino-3-(4-fluorobenzoyl)-phenylacetamide.

A solution of 24.2 g (0.07 mole) of 2-amino-3-(4-fluorobenzoyl)-α-(n-propylthio)phenylacetamide in 300 ml of tetrahydrofuran was treated with 250 g of wet Raney nickel (washed 3 times with water and 3 times with tetrahydrofuran). The mixture was stirred for one hour and filtered. The filtrate was concentrated under vacuum and the residue was recrystallized from 95% ethyl alcohol to give 14.8 g (78%) of yellow needles melting at 184-186°C.

**Analysis:** Calculated for C₁₅H₁₃N₂O₂F: C, 66.17; H, 4.81; N, 10.29

Found: C, 66.32; H, 4.81; N, 10.48

**Example 8**

In the same manner as given in Example 2, 2-amino-3-(2-fluorobenzoyl)phenylacetamide, 2-amino-3-(2,4-dichlorobenzoyl)phenylacetamide, 2-amino-3-(2,4-difluorobenzoyl)phenylacetamide, and 2-amino-3-(4-trifluoromethylbenzoyl)phenylacetamide are prepared from 2-amino-3-(2-fluorobenzoyl)-α-(phenylthio)phenylacetamide, 2-amino-3-(2,4-dichlorobenzoyl)-α-(phenylthio)phenylacetamide, 2-amino-3-(2,4-difluorobenzoyl)-α-(phenylthio)phenylacetamide, and 2-amino-3-(4-trifluoromethylbenzoyl)-α-(phenylthio)phenylacetamide.
Example 9
2-Amino-3-(4-methylthiobenzoyl)phenylacetamide.
The title compound is prepared by refluxing 2-amino-
3-(4-fluorobenzoyl)phenylacetamide with excess sodium methyl
mercaptide in ethanol and isolated by suitable means.

Example 10
2-Amino-3-(4-oxydimethylthiobenzoyl)phenylacetamide.
The title compound is prepared by reacting one mole of
2-amino-3-(4-methylthiobenzoyl)phenylacetamide with one mole
of sodium metaperiodate and isolated by suitable means.

Example 11
2-Amino-3-(4-dioxidimethylthiobenzoyl)phenylacetamide.
The title compound is prepared by reacting one mole of
2-amino-3-(4-methylthiobenzoyl)phenylacetamide with two
moles of sodium metaperiodate and isolated by suitable means.

Example 12
2-Amino-3-benzoyl-5-chloro-N-methylphenylacetamide.
A solution of 28.335 g (0.081 mole) of 2-amino-3-benzoyl-
5-chloro-N-(methylthio)-N-methylacetamide in one liter of
tetrahydrofuran was treated with excess Raney nickel at room
temperature for 2 hr. The solution was filtered through
celite. The Raney nickel residue was washed with acetone
and the wash filtered. The combined organic filtrates were
dried over magnesium sulfate and the volume reduced to about
300 ml. Excess ether was added and the solution allowed to
stand at room temperature for one hr followed by refrigeration
overnight. The yellow solid collected and dried weighed
20.94 g (85.68%) and melted at 179-180°C.

Analysis: Calculated for C₁₅H₁₅N₂O₂Cl: C, 63.48; H, 4.99;
N, 9.25
Found: C, 63.44; H, 4.99;
N, 9.27
Example 13

3-Benzoyl-2-(N-methylamino)-phenylacetamide.

When in the procedure of Example 2, 3-benzoyl-2-(N-methylamino)-α-(methylthio)phenylacetamide is substituted for 2-amino-3-benzoyl-α-(methylthio)phenylacetamide, the title compound is obtained.

Example 14

3-Benzoyl-2-(N,N-dimethylamino)-phenylacetamide.

A solution of 12.7 g (0.05 mol) of 2-amino-3-benzoyl-phenylacetamide in 150 ml of acetonitrile is treated four times with 16 ml (0.2 mole) of 37% formalin, 6.4 g (0.1 mole) of sodium cyanoborohydride and 2 ml of glacial acetic acid with a 15 minute stirring period between each treatment. The mixture is finally poured into dilute sodium hydroxide and extracted three times with diethylether. The ether extracts are combined, dried over magnesium sulfate and concentrated. The product is isolated by column chromatography.
Formulation and Administration

The present invention also contemplates novel compositions containing the compounds of the invention as active ingredients. Effective quantities of any of the foregoing pharmacologically active compounds may be administered to a living animal body in any one of various ways, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. In forming the novel compositions of this invention, the active ingredient is incorporated in a suitable carrier, illustratively, a pharmaceutical carrier. Suitable pharmaceutical carriers which are useful in formulating the compositions of this invention include starch, gelatin, glucose, magnesium carbonate, lactose, malt and the like. Liquid compositions are also within the purview of this invention and suitable liquid pharmaceutical carriers include ethyl alcohol, propylene glycol, glycerine, glucose syrup and the like.

The pharmacologically active compounds may be advantageously employed in a unit dosage of from 0.1 to 250 milligrams or more depending on the size of the animal. For example, a large animal such as a horse may require tablets of 500-1000 mg active ingredient. The unit dosage may be given a suitable number of times daily so that the daily dosage may vary from 0.3 to 450 milligrams. Five to 25 milligrams appears optimum per unit dose.

It is only necessary that the active ingredient constitute an effective amount, i.e., such that a suitable effective dosage will be obtained consistent with the dosage form employed. The exact individual dosages as well as daily dosages will, of course, be determined according to standard medical principles under the direction of a physician or veterinarian.

The active agents of the invention may be combined with other pharmacologically active agents, or with buffers, antacids or the like, for administration and the proportion
of the active agent in the compositions may be varied widely.

The following are examples of compositions formed in accordance with this invention.

1. **Capsules**

Capsules of 5 mg., 25 mg., and 50 mg. of active ingredient per capsule are prepared. With the higher amounts of active ingredient, adjustment may be made in the amount of lactose.

<table>
<thead>
<tr>
<th>Typical blend for encapsulation</th>
<th>Per capsule, mg.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active ingredient</td>
<td>5.0</td>
</tr>
<tr>
<td>Lactose</td>
<td>296.7</td>
</tr>
<tr>
<td>Starch</td>
<td>129.0</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>4.3</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>435.0 mg.</td>
</tr>
</tbody>
</table>

Additional capsule formulations preferably contain a higher dosage of active ingredient and are as follows.

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Per capsule, mg.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active ingredient</td>
<td>25.0</td>
</tr>
<tr>
<td>Lactose</td>
<td>306.5</td>
</tr>
<tr>
<td>Starch</td>
<td>99.2</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>4.3</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>435.0 mg.</td>
</tr>
</tbody>
</table>

In each case, uniformly blend the selected active ingredient with lactose, starch, and magnesium stearate and encapsulate the blend.

2. **Tablets**

A typical formulation for a tablet containing 5.0 mg. of active ingredient per tablet follows. The formulation may be used for other strengths of active ingredient by adjustment of weight of dicalcium phosphate.
Per tablet, mg.

(1) Active ingredient  5.0
(2) Corn starch      13.6
(3) Corn starch (paste) 3.4
(4) Lactose          79.2
(5) Dicalcium phosphate 68.0
(6) Calcium stearate  0.9

170.1 mg.

Uniformly blend 1, 2, 4, and 5. Prepare 3 as a 10 percent paste in water. Granulate the blend with starch paste and pass the wet mass through an eight mesh screen. The wet granulation is dried and sized through a twelve mesh screen. The dried granules are blended with the calcium stearate and pressed.

3. Injectable - 2% sterile solutions.

Per cc.

Active ingredient .......... 20 mg.
Preservative, e.g.,
chlorobutanol ............ 0.5% weight/volume
Water for injection ....... q.s.

Prepare solution, clarify by filtration, fill into vials, seal and autoclave.

Various modifications and equivalents will be apparent to one skilled in the art and may be made in the compounds, compositions, and methods of the present invention without departing from the spirit or scope thereof, and it is therefore understood that the invention is to be limited only by the scope of the appended claims.
The claims defining the invention are as follows:

- 1 -

A compound selected from the group having the formula:

\[
\text{R}^1 \text{Am} \text{N} \text{R}^2 \text{O} \text{CH} \text{C} \text{-N} \text{R}^1 \text{CH} \text{C} \text{O} \text{(Y)} \text{n}
\]

wherein;

- R is hydrogen and lower alkyl,
- R\(^1\) and R\(^2\) are selected from hydrogen, lower alkyl, cycloalkyl, phenyl and phenyl substituted by lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, and R\(^1\) and R\(^2\) when taken together with the adjacent nitrogen form a heterocyclic residue,
- X is hydrogen, lower alkyl, lower alkoxy, halogen and trifluoromethyl,
- Y is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkylthio, lower alkoxythio or lower alkylthioxythio,
- Am is primary amino (-NH\(_2\)), methylamino or dimethylamino, and
- n is 1-3 inclusive.

- 2 -

The compound of claim 1 which is 2-amino-3-benzoyl-5-chlorophenylacetamide.

- 3 -

The compound of claim 1 which is 2-amino-3-benzoyl-phenylacetamide.

- 4 -

The compound of claim 1 which is 2-amino-3-(4-chlorobenzoyl)phenylacetamide.
The compound of claim 1 which is 4-[2-(2-amino-3-benzoylphenyl)acetyl]morpholine.

The compound of claim 1 which is 2-amino-3-benzoyl-N-methylphenylacetamide.

The compound of claim 1 which is 2-amino-3-benzoyl-N,N-dimethylphenylacetamide.

The compound of claim 1 which is 2-amino-3-(4-fluorobenzoyl)phenylacetamide.

The compound of claim 1 which is 2-amino-3-benzoyl-5-chloro-N-methylphenylacetamide.

The method of alleviating inflammation in a living animal body with a minimum of undesirable side effects comprising internally administering to said living animal body an effective amount of a compound selected from the group having the formula:

\[
\begin{array}{c}
\text{CH-C-N} \\
\text{R^1} \\
\text{R^2} \\
\text{C=O} \\
\end{array}
\]

wherein;

R is hydrogen and lower alkyl, 
R^1 and R^2 are selected from hydrogen, lower alkyl, cycloalkyl, phenyl and phenyl substituted by lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, and R^1 and R^2 when taken together with the adjacent nitrogen form a heterocyclic residue.
X is hydrogen, lower alkyl, lower alkoxy, halogen and trifluoromethyl,
Y is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkylthio, lower alkyloxythio or lower alkyl(dioxythio),
Am is primary amino (—NH₂), methylamino or dimethylamino, and
n is 1-3 inclusive.

10 A method of claim 10 wherein the compound administered is 2-amino-3-benzoyl-5-chlorophenylacetamide.
15 The method of claim 10 wherein the compound administered is 2-amino-3-benzoylphenylacetamide.
20 The method of claim 10 wherein the compound administered is 2-amino-3-(4-chlorobenzoyl)phenylacetamide.
25 The method of claim 10 wherein the compound administered is 4-[2-(2-amino-3-benzoylphenyl)acetyl]morpholine.
30 The method of claim 10 wherein the compound is 2-amino-3-(4-fluorobenzoyl)phenylacetamide.
The method of producing an inhibitory effect on blood platelet aggregation which comprises administering to a living animal body a blood platelet inhibitory effective amount of a compound having the formula:

\[
\begin{align*}
&\text{wherein;} \\
&R \text{ is hydrogen and lower alkyl,} \\
&R^1 \text{ and } R^2 \text{ are selected from hydrogen, lower alkyl, cycloalkyl, phenyl and phenyl substituted by lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, and } R^1 \\
&\text{and } R^2 \text{ when taken together with the adjacent nitrogen form a heterocyclic residue,} \\
&X \text{ is hydrogen, lower alkyl, lower alkoxy, halogen and trifluoromethyl,} \\
&Y \text{ is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkylthio, lower alkyloxythio or lower alkylthiothio,} \\
&A \text{m is primary amino } (-\text{NH}_2), \text{ methylamino or dimethylamino, and} \\
&n \text{ is 1-3 inclusive.}
\end{align*}
\]

The method of producing an analgetic effect in a living animal body afflicted with pain which comprises administering to a living animal body an analgetic effective amount of a compound having the formula:
wherein:

- $R$ is hydrogen and lower alkyl,
- $R^1$ and $R^2$ are selected from hydrogen, lower alkyl, cycloalkyl, phenyl and phenyl substituted by lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, and $R^1$ and $R^2$ when taken together with the adjacent nitrogen form a heterocyclic residue,
- $X$ is hydrogen, lower alkyl, lower alkoxy, halogen and trifluoromethyl,
- $Y$ is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkylthio, lower alkyloxythio or lower alkylidioxythio,
- $Am$ is primary amino ($-\text{NH}_2$), methylamino or dimethylamino, and
- $n$ is 1-3 inclusive.

A therapeutic composition suitable for alleviating inflammation with minimal side effects comprising (a) an effective amount of a compound selected from the group having the formula:
wherein:

R is hydrogen and lower alkyl,

R₁ and R² are selected from hydrogen, lower alkyl, cycloalkyl, phenyl and phenyl substituted by lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, and R₁ and R² when taken together with the adjacent nitrogen form a heterocyclic residue,

X is hydrogen, lower alkyl, lower alkoxy, halogen and trifluoromethyl,

Y is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkylthio, lower alkylthio or lower alkyldioxythio,

Am is primary amino (–NH₂), methylamino and dimethylamino,

n is 1-3 inclusive, and

(b) a pharmaceutically acceptable carrier therefor.

The therapeutic composition of claim 21 wherein the compound is 2-amino-3-benzoyl-5-chlorophenylacetamide.

The composition of claim 21 wherein the compound is 2-amino-3-benzoylphenylacetamide.

The composition of claim 21 wherein the compound is 2-amino-3-(4-chlorobenzoyl)phenylacetamide.

The composition of claim 21 wherein the compound is 4-[2-(2-amino-3-benzoylphenyl)acetyl]morpholine.

The composition of claim 21 wherein the compound is 2-amino-3-benzoyl-N-methylphenylacetamide.

The composition of claim 21 wherein the compound is 2-amino-3-benzoyl-N,N-dimethylphenylacetamide.
The composition of claim 21 wherein the compound is 2-amino-3-(4-fluorobenzoyl)phenylacetamide.

The composition of claim 21 wherein the compound is 2-amino-3-benzoyl-5-chloro-N-methylphenylacetamide.

DATED this 5th day of September, 1980.

A. H. ROBINS COMPANY, INC.
By Their Patent Attorneys
ARTHUR S. CAVE & CO.